1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Gilead Sciences, Inc.

Gilead Sciences, Inc.

GIS.DE
Gilead Sciences, Inc.DE flagDeutsche Börse
119.08
EUR
+1.74
- -
147.85BMarket Cap
Gilead Sciences, Inc.
GIS.DE
(Deutsche Börse)

Recent

price

119.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.64
5.41
6.41
7.33
16.35
22.29
22.7
19.97
17.05
17.68
19.64
21.74
21.74
21.73
23.06
23.67
23.92
Revenue per Share
1.69
1.81
1.71
2.01
7.95
12.37
10.08
3.54
4.2
4.24
0.1
4.96
3.66
4.54
0.38
6.84
7.41
Basic EPS, GAAP
1.66
2.35
2.11
2.03
8.42
14.52
12.73
9.1
6.47
7.2
6.5
9.06
7.23
5.95
8.26
7.6
8.23
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
1.28
1.83
2.09
2.29
2.54
2.74
2.87
2.96
3.05
3.14
3.22
3.24
Dividend per Share
0.69
1.15
2.45
4
8.37
12.3
13.56
14.55
14.66
15.27
11.44
13
12.5
13.06
9.22
11.04
11.37
Book Value per Share
2.74
3.1
-2.15
-0.87
2.35
5.26
6.89
-0.58
1.29
3.74
-18.31
-16.5
-12.75
-9.63
-7.23
-2.15
-1.02
Tangible Book Value per Share
1,712
1,550
1,515
1,529
1,522
1,464
1,339
1,307
1,298
1,270
1,257
1,256
1,255
1,248
1,247
1,244
1,243
Basic Weighted Avg Shares
7,949
8,385
9,702
11,202
24,890
32,639
30,390
26,107
22,127
22,449
24,689
27,305
27,281
27,116
28,754
29,442
29,734
Sales/Revenue/Turnover
49.84
45.2
41.33
40.39
61.33
68
58.02
54.1
42.02
41.6
40.21
39.76
40.23
32.59
36.85
39.74
40.02
Operating Margin (%)
265
302
278
345
1,050
1,098
1,158
1,286
1,429
1,404
1,480
2,050
2,103
2,693
2,767
2,760
2,753
Depreciation Expense
2,901
2,804
2,592
3,075
12,101
18,108
13,501
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
9,216
Net Income, GAAP
26.16
23.61
28.74
27.35
18.83
16.4
21.11
65.67
29.99
- -
94.67
25.09
21.47
18.18
30.58
13.13
14.08
Effective Tax Rate (%)
36.5
33.43
26.72
27.45
48.62
55.48
44.43
17.73
24.65
23.99
0.5
22.8
16.83
20.89
1.67
28.9
30.99
Profit Margin (%)
3,243
11,404
1,918
590
11,953
14,872
10,370
20,188
25,231
20,537
4,599
3,162
3,205
4,805
7,169
6,529
9,166
Working Capital
2,839
7,606
7,055
3,939
11,921
21,073
26,346
30,795
24,574
22,094
28,645
25,179
22,957
23,189
24,896
22,129
20,861
LT Debt
6,122
6,867
9,544
11,745
15,819
19,113
19,363
20,501
21,534
22,650
18,221
21,064
21,209
22,749
19,246
22,618
23,431
Total Equity
33.67
24.36
17.96
18.43
53.74
54.43
32.6
9.75
12.67
- -
1.1
16.76
18.29
15.25
15.52
21.77
23.25
Return on Invested Capital (%)
72.04
41.2
26.44
26.22
64.57
56.48
33.35
10.24
12.52
- -
0.47
15.76
12.76
15.81
2.92
24.51
27.99
Return on Capital (%)
182.43
189.3
94.53
62.66
128.45
117.83
74.68
24.9
28.68
28.04
0.73
40.54
28.69
35.41
3.45
67.46
73.54
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2,806
2,807
1,313
LT Borrowings
22,135
22,129
20,861
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,242
1,241
1,242
Market Capitalization
140,127
155,365
172,155

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
17,874
18,342
18,641
Cash, Cash Equivalents & STI
7,349
9,613
7,643
Accounts Receivable, Net
5,095
4,913
4,741
Inventories
1,785
1,774
1,914
Total Current Liabilities
12,297
11,813
9,475
Payables & Accruals
5,739
5,144
4,763
ST Debt
2,806
2,807
1,313
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.35%
5.13%
17.52%
Free Cash Flow
-4.97%
6.3%
-8.24%
Net Income, GAAP
636.72%
1,307.9%
1,672.92%
Sales/Revenue/Turnover
-0.64%
3.67%
2.39%
Total Cash Common Dividend
8.17%
3.03%
2.17%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,686
6,953
7,545
7,569
28,754
2025
6,667
7,081
7,769
7,924
29,442
2026
6,960
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.34
1.29
1
1.43
0.38
2025
1.06
1.57
- -
1.76
6.84
2026
1.63
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.79
0.78
0.79
0.78
3.14
2025
0.81
0.8
- -
0.8
3.22
2026
0.84
- -
- -
- -
- -
Similar Companies
Organon & Co. (OGN)
PT Kalbe Farma Tbk. (KLBF.JK)
PharmGen Science, Inc. (004720.KS)
Roche Holding AG (0QQ6.L)
Shandong Jintai Group Co., Ltd. (600385.SS)
Dimed S.A. Distribuidora de Medicamentos (PNVL3.SA)
Business
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in virology, oncology and inflammation. The company offers more than 25 medicines globally, including HIV treatments such as Biktarvy, Descovy, Truvada, Genvoya and the twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP); hepatitis therapies including Epclusa, Vemlidy and Harvoni; COVID-19 antiviral Veklury (remdesivir); oncology products through subsidiary Kite Pharma such as Yescarta and Tecartus for cell therapy in lymphoma and leukemia; and inflammation treatments including Trodelvy for solid tumors, Veklury for emerging viruses, and seladelpar for primary biliary cholangitis. Gilead Sciences operates in more than 35 countries worldwide with over 18,000 employees, targeting patients with life-threatening diseases in North America, Europe, Asia-Pacific and other regions. Founded in 1987 and headquartered in Foster City, California, the company maintains manufacturing sites in California, Connecticut and Canada, alongside research hubs including a new facility in Oxford, England, opened in 2024. Recent developments include the 2024 acquisition of CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio with seladelpar; the November 2025 acquisition of Sprint Bioscience's preclinical TREX1 oncology immunotherapy program for up to $400 million; a January 2025 strategic partnership with LEO Pharma for oral STAT6 inhibitors and protein degraders in inflammation; groundbreaking in September 2025 on a new 180,000-square-foot AI-enabled manufacturing and development hub in Foster City as part of a $32 billion U.S. investment commitment projected to create thousands of jobs and $43 billion in economic value; U.S. FDA approval in July 2025 of a new Biktarvy indication for treatment-experienced HIV patients restarting therapy; and agreements with the Global Fund in 2025 to accelerate twice-yearly lenacapavir access in low- and lower-middle-income countries.